目的 探討坤寶丸聯(lián)合替勃龍治療圍絕經(jīng)期綜合征的臨床療效。方法 選取2021年10月—2024年8月首都醫(yī)科大學(xué)附屬北京康復(fù)醫(yī)院收治的84例圍絕經(jīng)期綜合征患者，按隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各42例。對(duì)照組口服替勃龍片，1片/次，1次/d。治療組在對(duì)照組治療基礎(chǔ)上口服坤寶丸，50 丸/次，2次/d。兩組療程均為3個(gè)月。觀察兩組臨床療效，比較兩組治療前后改良Kupperman絕經(jīng)指數(shù)（KMI）、癥狀自評(píng)量表（SCL-90）、絕經(jīng)期生存質(zhì)量量表（MENQOL）評(píng)分及血清性激素水平和白細(xì)胞介素（IL）-1β、IL-8、超氧化物歧化酶（SOD）水平。結(jié)果 治療后，治療組總有效率是95.24%，顯著高于對(duì)照組的80.95%（P＜0.05）。治療后，兩組患者改良KMI、SCL-90和MENQOL評(píng)分都低于同組治療前（P＜0.05）；治療后，治療組改良KMI、SCL-90和MENQOL評(píng)分都低于對(duì)照組（P＜0.05）。治療后，兩組血清促黃體生成素（LH）、卵泡刺激素（FSH）水平都低于同組治療前，雌二醇（E₂）水平顯著升高（P＜0.05）；治療后，治療組LH、FSH水平低于對(duì)照組，治療組血清E₂水平高于對(duì)照組（P＜0.05）。治療后，兩組血清IL-1β、IL-8水平都低于同組治療前，兩組血清SOD水平都顯著上升（P＜0.05）；治療后，治療組血清IL-1β、IL-8水平低于對(duì)照組，血清SOD水平高于治療組（P＜0.05）。結(jié)論 坤寶丸聯(lián)合替勃龍治療圍絕經(jīng)期綜合征具有較好的療效，能有效調(diào)節(jié)機(jī)體性激素水平、減輕患者癥狀，并能明顯抑制機(jī)體炎癥及自由基損害，改善患者身心狀態(tài)及生存質(zhì)量。

Objective To explore the clinical efficacy of Kunbao Pills combined with tibolone in treatment of perimenopausal syndrome. Methods A total of 84 patients with perimenopausal syndrome admitted to Beijing Rehabilitation Hospital Affiliated to Capital Medical University from October 2021 to August 2024 were selected and divided into control group and treatment group according to random number table method, with 42 cases in each group. Patients in control group were po administered with Tibolone Tablets, 1 tablet/time, once daily. Patients in treatment group were po administered with Kunbao Pills on the basis of the control group, 50 pills/time, twice daily. The treatment course of both groups was 3 months. The clinical effects of two groups were observed, and the modified Kupperman Menopause index (KMI), Symptom Checklist 90 (SCL-90), Menopause Quality of Life Scale (MENQOL) scores, serum sex hormone levels, IL-1β, IL-8, and superoxide dismutase (SOD) levels were compared between two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 95.24%, which was significantly higher than that of the control group (80.95%, P < 0.05). After treatment, the improved KMI, SCL-90 and MENQOL scores in two groups were lower than before treatment (P < 0.05). After treatment, the improved KMI, SCL-90 and MENQOL scores in treatment group were lower than those in control group (P < 0.05). After treatment, serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in two groups were lower than before treatment, and estradiol (E₂) levels were significantly increased (P < 0.05). After treatment, the level of LH and FSH in treatment group was lower than that in control group, and the level of serum E₂ in treatment group was higher than that in control group (P < 0.05). After treatment, serum IL-1β and IL-8 levels in two groups were lower than before treatment, and serum SOD levels in two groups were significantly increased (P< 0.05). After treatment, the serum levels of IL-1β and IL-8 in treatment group were lower than those in control group, and the serum level of SOD was higher than that in treatment group (P < 0.05). Conclusion Kunbao Pills combined with tibolone has good curative effect in treatment of perimenopausal syndrome, and can effectively regulate the body sex hormone level, reduce the symptoms of patients, and significantly inhibit the body inflammation and free radical damage, which can improve the physical and mental state and life quality of patients.

R984

首都醫(yī)科大學(xué)附屬北京康復(fù)醫(yī)院科研發(fā)展專項(xiàng)資助項(xiàng)目（2020-057）